Dr Liu on the Significance of T-DXd For Patients With HER2-Mutant NSCLC and Brain Metastases
Stephen V. Liu, MD, discusses the significance of using fam-trastuzumab deruxtecan-nxki in patients with HER2-mutant non–small cell lung cancer and brain metastases according to pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials.
Source: onclive.com